Literature DB >> 12940374

Intravenous immunoglobulins in severe Guillian-Barre syndrome in childhood.

Preeti Shanbag1, Cynthia Amirtharaj, Ashish Pathak.   

Abstract

OBJECTIVE: This is a retrospective analysis of 25 children with severe Guillain-Barre syndrome admitted to our PICU.
METHOD: All children were treated with intravenous immunoglobulins (IVIG) in a dose of 2 g/kg body weight over 2-5 days in addition to supportive and respiratory care. Seventeen children were elective admissions to the PICU whereas 8 children were transferred from other hospitals in a critical condition. Five of 8 of the late referrals died as compared to none of the elective admissions. RESULT: All 8 of the late referrals required mechanical ventilation as against 3 of the 17 elective admissions. Mean duration of PICU stay in the late referrals was 27 days as compared to 15 days in the elective admissions.
CONCLUSION: The authors concur with previously published reports, that early use of IVIG could reduce the mortality and the need for intubation and mechanical ventilation.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12940374     DOI: 10.1007/bf02723152

Source DB:  PubMed          Journal:  Indian J Pediatr        ISSN: 0019-5456            Impact factor:   1.967


  13 in total

1.  Benefit of intravenously administered immune serum globulin in patients with Guillain-Barré syndrome.

Authors:  E Shahar; E G Murphy; C M Roifman
Journal:  J Pediatr       Date:  1990-01       Impact factor: 4.406

2.  Immune globulins are effective in severe pediatric Guillain-Barré syndrome.

Authors:  E Shahar; Z Shorer; C M Roifman; Y Levi; N Brand; S Ravid; E G Murphy
Journal:  Pediatr Neurol       Date:  1997-01       Impact factor: 3.372

Review 3.  Assessment of current diagnostic criteria for Guillain-Barré syndrome.

Authors:  A K Asbury; D R Cornblath
Journal:  Ann Neurol       Date:  1990       Impact factor: 10.422

Review 4.  Intravenous immunoglobulin as therapy for pediatric Guillain-Barré syndrome.

Authors:  S A Abd-Allah; P W Jansen; S Ashwal; R M Perkin
Journal:  J Child Neurol       Date:  1997-09       Impact factor: 1.987

5.  Intravenous immunoglobulin in two children with Guillain-Barré syndrome.

Authors:  L D Notarangelo; M Duse; S Tiberti; B Guarneri; A Brunori; A Negrini; A G Ugazio
Journal:  Eur J Pediatr       Date:  1993-04       Impact factor: 3.183

6.  Plasmapheresis vs intravenous immunoglobulin treatment in childhood Guillain-Barré syndrome.

Authors:  J Vajsar; A Sloane; E Wood; E G Murphy
Journal:  Arch Pediatr Adolesc Med       Date:  1994-11

7.  Criteria for diagnosis of Guillain-Barré syndrome.

Authors: 
Journal:  Ann Neurol       Date:  1978-06       Impact factor: 10.422

8.  Intravenous immunoglobulin treatment in children with Guillain-Barré syndrome.

Authors:  G Kanra; A Ozon; J Vajsar; L Castagna; G Secmeer; H Topaloglu
Journal:  Eur J Paediatr Neurol       Date:  1997       Impact factor: 3.140

9.  Natural history and treatment effects in Guillain-Barré syndrome: a multicentre study.

Authors:  R Korinthenberg; J S Mönting
Journal:  Arch Dis Child       Date:  1996-04       Impact factor: 3.791

10.  Severe Guillain-Barré syndrome in childhood treated with human immune globulin.

Authors:  R C Reisin; J Pociecha; E Rodriguez; M E Massaro; H A Arroyo; N Fejerman
Journal:  Pediatr Neurol       Date:  1996-05       Impact factor: 3.372

View more
  2 in total

1.  Improvement in Lasegue's sign: an early predictor of recovery in childhood Guillain-Barre syndrome.

Authors:  Arun K Baranwal; Ravi N Mandal; Rupa Singh
Journal:  Indian J Pediatr       Date:  2006-03       Impact factor: 5.319

2.  Spectrum of Guillain-Barré syndrome in tertiary care hospital at Kolkata.

Authors:  Ujjal Kr Sarkar; Lalita Menon; Debabrata Sarbapalli; Ranabir Pal; Forhad Akhtar Zaman; Sumit Kar; Jyoti Singh; Mohan Mondal; Soma Mukherjee
Journal:  J Nat Sci Biol Med       Date:  2011-07
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.